Alle Fälle anzeigen
ORD 59318/2024
—·EP4026488: TRANSCUTANEOUS ANALYTE SENSOR SYSTEMS AND METHODS
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieVerfahrensführungsanordnungen
- Parteien
- KlägerVertreter: Markus Grosch (Quinn Emanuel Urquhart & Sullivan LLP); Johannes Bukow (Quinn Emanuel Urquhart & Sullivan LLP); Jan Axtmann (Quinn Emanuel Urquhart & Sullivan LLP); Paul Lehmann (Quinn Emanuel Urquhart & Sullivan LLP)Beklagte
- Abbott Logistics B.V.
- Abbott Laboratories GmbH
- Abbott Laboratories
- Abbott Oy
- Abbott Scandinavia Aktiebolag
- Abbott (S.A./N.V.)
- Abbott B.V.
- Abbott France (S.A.S.)
- Abbott GmbH
- Abbott Diagnostics GmbH
- Abbott Gesellschaft m.b.H.
- Abbott Diabetes Care Inc.
- Abbott s.r.l.
Vertreter: Dietrich Kamlah (Taylor Wessing); Christian Lederer (Taylor Wessing); Gisbert Hohagen (Taylor Wessing) - Division
- Dusseldorf LD
- Richter
- Berenice Thom · Legally Qualified Judge
- Petri Rinkinen · Legally Qualified Judge
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 21. Nov. 2024
Entscheidungen
- 2024-11-21Generic Order
The Düsseldorf Local Division issued a procedural order in the DexCom v. Abbott infringement action concerning EP 4 026 488, taking an early decision pursuant to R. 37.2 RoP on how to proceed under Art. 33(3) UPCA (bifurcation or combined hearing of infringement and validity). The court exercised its discretion to hear both the infringement action and any counterclaim for revocation together.
Rechtsfragen:Early decision on Art. 33(3) UPCA bifurcation (R. 37.2 RoP)Combined hearing of infringement and revocationJurisdiction and case management in large multi-party infringement actions
Dokumente
- 68DD1EEC711076C2DF523095A0F136E4_en.pdf2024-11-21EN